- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027387
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
Study Overview
Detailed Description
This phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation study will evaluate the safety, tolerability and pharmacokinetic (PK) parameters of TMB-365 administered via intravenous infusion (IV) to HIV-1 infected participants at one of three successively increasing dose levels: 400 mg, 800 mg, and 1600 mg. Each participant will be monitored for 10 weeks post-administration. All participants will be expected to participate in PK sampling during Weeks 1, 4, 5, and 6.
Beginning with the lowest dosage group, a Data Monitoring Committee (DMC) will review available data after four participants have completed two weeks of post-dose follow-up to determine if dosing of the next dosage group may proceed.
If no dose limiting toxicities (DLTs) emerge, defined as a single Grade 4 or two of the same Grade 3 clinical or laboratory adverse events deemed possibly, probably or definitely related to the study drug, or a serious adverse event deemed possibly, probably or definitely related to the study drug as graded by the DAIDS Table for Grading Severity of Adult and Pediatric Adverse Events Version 2.1, then dosing of the next higher dose group will be permitted.
Dosing in the highest dose group will begin after four of the eight participants in second group have successfully completed the scheduled study drug administration and two weeks of follow-up, and those data, along with all available data from the initial dose group have been reviewed by the DMC and no DLTs or SAEs as defined above are identified.
All participants may initiate standard combination antiretroviral therapy six weeks after receiving the study drug.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00909
- Clinical Research PR, Inc
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Quest Clinical Research
-
-
Florida
-
Fort Pierce, Florida, United States, 34982
- Midway Immunology and Research Center
-
Orlando, Florida, United States, 32803
- Orlando Immunology Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39213
- University of Mississippi Medical Center Division of Infectious Diseases
-
-
Texas
-
Dallas, Texas, United States, 75246
- North Texas Infectious Disease Consultants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female at least 18 years of age and no greater than 60 years on the day of Screening
- Asymptomatic HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load
- Has not received ART for three months prior to the first dose.
- Screening HIV-1 RNA ≥ 1,000 copies/mL and < 100,000 copies/mL obtained within 60 days prior to the first dose.
Laboratory values obtained within 60 days prior to the first dose:
- Hemoglobin > 10.0 g/dL
- Platelet count ≥ 100,000/mm3
- Absolute neutrophil count ≥ 1,000/mm3
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)
- Creatinine clearance (CrCl) of ≥ 50 mL/min
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- In the opinion of the principal investigator or designee, has understood the information provided; written informed consent needs to be given before any study-related procedures are performed
- Females of childbearing potential, sexually active with a male sex partner, must agree to use one effective method of contraception from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Females of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not postmenopausal (at least one year without menses), and are not otherwise sterile by medical evaluation.
Exclusion Criteria:
- Receipt of TMB-365, TROGARZO (ibalizumab-uiyk), or any anti-CD4 therapeutic (e.g., UB-421) at any time prior to the first dose
- Pregnant, planning a pregnancy during the trial period, or lactating.
- Known allergy/sensitivity or any hypersensitivity to components of the study drug or its formulation, or known allergy to a MAb
- Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt in the previous three years
- Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to the first dose
- Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic corticosteroids), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to the first dose
- Any chronic or acute medical condition, including drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug
- Lack of adequate venous access
- Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens. Note that a change in treatment regimen for intolerance is not considered treatment failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TMB-365 400 mg- Group 1
Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
|
An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
|
Experimental: TMB-365 800 mg- Group 2
Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
|
An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
|
Experimental: TMB-365 1600 mg- Group 3
Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
|
An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of a single 400mg dose of TMB-365
Time Frame: 10 weeks
|
% of subjects with treatment-emergent adverse events
|
10 weeks
|
Safety of a single 800mg dose of TMB-365
Time Frame: 10 weeks
|
% of subjects with treatment-emergent adverse events
|
10 weeks
|
Safety of a single 1600mg dose of TMB-365
Time Frame: 10 weeks
|
% of subjects with treatment-emergent adverse events
|
10 weeks
|
Pharmacokinetics of a single 400mg dose of TMB-365
Time Frame: 4 weeks
|
% CD4 receptor occupancy
|
4 weeks
|
Pharmacokinetics of a single 800mg dose of TMB-365
Time Frame: 4 weeks
|
% CD4 receptor occupancy
|
4 weeks
|
Pharmacokinetics of a single 1600mg dose of TMB-365
Time Frame: 4 weeks
|
% CD4 receptor occupancy
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antiviral activity of a single 400 mg dose of TMB-365
Time Frame: 2 weeks
|
Change in log10 plasma HIV-1 RNA
|
2 weeks
|
Antiviral activity of a single 800 mg dose of TMB-365
Time Frame: 2 weeks
|
Change in log10 plasma HIV-1 RNA
|
2 weeks
|
Antiviral activity of a single 1600 mg dose of TMB-365
Time Frame: 2 weeks
|
Change in log10 plasma HIV-1 RNA
|
2 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Steve Weinheimer, PhD, TaiMed Biologics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TMB-365-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on TMB-365
-
TaiMed Biologics Inc.Recruiting
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbTerminatedNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage III | Non-Small Cell Carcinoma of LungFrance
-
TaiMed Biologics Inc.TerminatedHuman Immunodeficiency VirusUnited States
-
USDA Food and Nutrition ServiceMathematica Policy Research, Inc.CompletedFood Insecurity Among Children
-
Rutgers, The State University of New JerseyNational Institute of Mental Health (NIMH); Positive Impact Health Centers; THRIVE...CompletedMedication Adherence | Depressive Symptoms | Anxiety Symptoms | Emotion RegulationUnited States
-
Sironax USA, Inc.CompletedCorona Virus InfectionPakistan, United States, Mexico
-
Rutgers, The State University of New JerseyColumbia University; Emory University; George Washington University; Arizona State... and other collaboratorsNot yet recruitingMedication Adherence | Depressive Symptoms | Anxiety Symptoms | Social Stigma | Sexual and Gender Minorities
-
Atamyo TherapeuticsRecruiting
-
Timber Pharmaceuticals Inc.Active, not recruitingIchthyosisUnited States, Canada, Germany, France, Italy
-
Leo WangBTS InternationalCompletedHypertension | Efficacy of Wrist BPM MeasurementChina